Please assess the completion status of the following clinical trial:

Trial Title: Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with steroid (or immunosuppressive therapy \[IST\]) refractory acute GVHD (aGVHD) or chronic GVHD (cGVHD)~* Absolute neutrophil count \>= 750/mm\^3~* Platelet count \>= 50,000/mm\^3~* Corrected QT interval (QTc) =\< 480 msec~* Bilirubin =\< 1.5 x upper limit of normal (ULN)~* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 x ULN~* Serum potassium \>= 3.8 mmol/L~* Serum magnesium \>= 1.8 mg/dL~* Serum creatinine =\< 2.0 mg/dl~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3~* Patients may undergo electrolyte repletion therapy to meet eligibility requirements~* Patients must be scheduled for tapering doses of (or no longer treated with):~  * Cyclosporine;~ * Tacrolimus;~ * Sirolimus;~ * Steroids (patients may be on physiologic doses of steroids)~* Patients receiving extracorporeal photopheresis must discontinue extracorporeal photopheresis or placed on a tapering schedule;~* Any prior therapy for GVHD must be completed and discontinued with the exception of the above;~* Patients with breakpoint cluster region (bcr)-ABL proto-oncogene 1 (abl) associated malignancies may be on a tyrosine kinase inhibitor as malignant disease therapy or prophylaxis~* There must be no uncontrolled active infections or medical conditions that the investigator feels will compromise the safety of the treatment and/or the assessment of the efficacy of therapy~* The patient must be aware of the high risk and experimental nature of the treatment and provide informed consent~* Negative serum pregnancy test at the time of enrollment for females of childbearing potential~* For males and females of child-producing potential, use of effective contraceptive methods during the study and for at least 6 months after the last dose of romidepsin~Exclusion Criteria:~* Active/uncontrolled infection~* Evidence of relapsed disease~* Life expectancy \< 12 weeks~* Pregnant or breast feeding females~* Prior therapy with romidepsin~* Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV); patients who are seropositive because of hepatitis B virus vaccine are eligible~* Any known cardiac abnormalities such as:~  * Congenital long QT syndrome~ * QTc interval \>= 480 milliseconds;~ * Myocardial infarction within 6 months of course 1, day 1 (C1D1); subjects with a history of myocardial infarction between 6 and 12 months prior to C1D1 who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may participate;~ * Other significant electrocardiogram (ECG) abnormalities including 2nd degree atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min);~ * Symptomatic coronary artery disease (CAD), e.g., angina Canadian class II-IV; in any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;~ * An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of \>= 2 mm, measured from isoelectric line to the ST segment); if in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present;~ * Congestive heart failure (CHF) that meets New York Heart Association (NYHA) class II to IV definitions and/or ejection fraction \< 40% by multi gated acquisition (MUGA) scan or \< 50% by echocardiogram and/or magnetic resonance imaging (MRI);~ * A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD);~ * Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other cause;~ * Any cardiac arrhythmia requiring an anti-arrhythmic medication (excluding stable doses of beta-blockers)~* Uncontrolled hypertension, i.e., blood pressure (BP) of \>= 160/95; patients who have a history of hypertension controlled by medication must be on a stable dose (for at least one month) and meet all other inclusion criteria; or~* Patients taking drugs leading to significant QT prolongation must have an ECG prior to each treatment~* Concomitant use of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors~* Concomitant use of medications known to induce a disulfiram-like reaction to alcohol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive care (romidepsin) (Type: EXPERIMENTAL): Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).